
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Keywords: بیماری ریه بینابینی; AE; adverse event; CI; confidence interval; CR; complete response; CT; computed tomography; DCR; disease control rate; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; FAS; full analysis set; HR; hazard ratio; ILD; interst